Financial News
Latest News about CRSP
Recent news which mentions CRSP
3 Reasons Why Cathie Wood Won't Touch This Warren Buffett Stock
September 29, 2022
From Motley Fool
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
September 28, 2022
From Benzinga
The 2 Best Stocks to Invest $5,000 in Right Now
September 28, 2022
From Motley Fool
Why Vertex Pharmaceuticals Stock Triumphed On Tuesday
September 27, 2022
From Motley Fool
What Is Going on With Grom Social (GROM) Stock Today?
September 27, 2022
From InvestorPlace
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today?
September 27, 2022
From InvestorPlace
Why Is Crispr Therapeutics (CRSP) Stock Up Today?
September 27, 2022
From InvestorPlace
Why CRISPR Therapeutics Stock Is Rising Today
September 27, 2022
From Benzinga
Recession Fears Increasing: Here's the Best Stock to Buy Right Now
September 24, 2022
From Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today
September 20, 2022
Tickers
CRSP
From Benzinga
"The Era of the Gene-Edited Human Is Here"
September 19, 2022
From Motley Fool
2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years
September 19, 2022
From Motley Fool
2 Biotech Stocks That Could Make You Richer
September 17, 2022
From Motley Fool
From Motley Fool
The Best Biotech Stock to Own in September
September 06, 2022
From Motley Fool
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
August 31, 2022
Tickers
CRSP
From Benzinga
3 Biotech Stocks You Can Buy and Hold for the Next Decade
August 29, 2022
From Motley Fool
3 Growth Stocks Poised to Skyrocket
August 27, 2022
From Motley Fool
5 Top Stocks Cathie Wood Is Selling This Week
August 26, 2022
From InvestorPlace
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
August 22, 2022
From InvestorPlace
3 Monster Stocks in the Making to Buy Right Now
August 20, 2022
From Motley Fool
From Benzinga
Stifel Raises Price Target for CRISPR Therapeutics (CRSP) to $69
August 13, 2022
Tickers
CRSP
From Best Stocks
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
August 09, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
August 09, 2022
From Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
August 09, 2022
From Benzinga
From Benzinga
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
